Numab is advancing a diversified pipeline of multispecific antibodies with first- and best-in-class potential and has established a strong track record of strategic partnerships with leading pharmaceutical companies. Its lead candidate NM26 is a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy in atopic dermatitis and other potential indications.
Cyborg Score Rationale
Numab demonstrates solid competitive positioning with a validated platform, strong pharma partnerships (Boehringer Ingelheim, Kaken Pharmaceutical, Ono Pharmaceutical), and significant funding of $228M raised to date. However, as a private company with mostly pre-clinical/early-stage programs, commercial execution risk remains.
Top Insights
In December 2025, Numab achieved a milestone in a second collaboration with Boehringer Ingelheim, which advanced a novel multi-specific antibody for retinal diseases into preclinical development.
In November 2025, Numab and Kaken Pharmaceutical announced a licensing and co-development agreement for multispecific antibody NM81 in inflammatory bowel disease, with Kaken committing to funding global development.
As of April 2026, Numab has raised $55M in funding, with the last funding round occurring in January 2025.
Barbara Angehrn Pavik joined as CEO in 2025, bringing more than two decades of EU and U.S. biopharma experience, including securing $100M Series C at Asceneuron and involvement in CSL's $11.7B acquisition of Vifor Pharma.
Named Competitors
CytomX Therapeutics — Multispecific and conditional antibody therapeutics
Regeneron Pharmaceuticals — Multispecific antibody and bispecific therapeutics for oncology and inflammation
Genmab — Bispecific and multispecific antibody therapeutics for cancer and inflammation
Merus — Bispecific antibody therapeutics platform for oncology and immunology
Recent Developments
(December 2025) Numab achieved development milestone in second Boehringer Ingelheim collaboration on retinal disease antibody
(November 2025) Licensing and co-development agreement with Kaken Pharmaceutical for NM81 in inflammatory bowel disease
(January 2025) Series funding round of $55M completed
(March 2026) Senior leadership addition of VP People & Culture from University Hospital Zurich
Open the full interactive Numab Therapeutics AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.